bastard-m 1
1. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
2. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
3. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
4. The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/ Rifampicin-Resistant Tuberculosis Cohort
5. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
6. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
7. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
8. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
9. Effect of smoking on drug-resistant tuberculosis treatment outcomes and potential mechanistic pathways: a multicountry cohort study
10. Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up
11. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
12. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
13. Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
1